You are 3 steps away
from making better decisions

Serving leading biopharmaceutical companies globally:

McKinsey
Baxter
Colorcon
Mallinckrodt
Johnson and Johnson
McKesson

Last Updated: August 8, 2020

DrugPatentWatch Database Preview

Aspen Company Profile

➤ Get the DrugPatentWatch Daily Briefing
» See Plans and Pricing

« Back to Dashboard

Summary for Aspen
International Patents:17
US Patents:2
Tradenames:11
Ingredients:12
NDAs:14

Drugs and US Patents for Aspen

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Exclusivity Expiration
Aspen ENJUVIA estrogens, conjugated synthetic b TABLET;ORAL 021443-003 May 10, 2004 DISCN No No 6,660,726   Start Trial Y Y   Start Trial
Aspen Global Inc HEXADROL dexamethasone TABLET;ORAL 012675-010 Approved Prior to Jan 1, 1982 DISCN No No   Start Trial   Start Trial
Aspen Global Inc HYDROXYPROGESTERONE CAPROATE hydroxyprogesterone caproate SOLUTION;INTRAMUSCULAR 200271-001 Aug 24, 2015 RX No Yes   Start Trial   Start Trial
Aspen CENESTIN estrogens, conjugated synthetic a TABLET;ORAL 020992-004 Mar 13, 2000 DISCN Yes No   Start Trial   Start Trial
Aspen HYDROXYPROGESTERONE CAPROATE hydroxyprogesterone caproate SOLUTION;INTRAMUSCULAR 211777-001 Aug 8, 2019 AP RX No No   Start Trial   Start Trial
Aspen Global Inc HEXADROL dexamethasone ELIXIR;ORAL 012674-001 Approved Prior to Jan 1, 1982 DISCN No No   Start Trial   Start Trial
>Applicant >Tradename >Generic Name >Dosage >NDA >Approval Date >TE >Type >RLD >RS >Patent No. >Patent Expiration >Product >Substance >Delist Req. >Exclusivity Expiration

Expired US Patents for Aspen

Applicant Tradename Generic Name Dosage NDA Approval Date Patent No. Patent Expiration
Aspen Global Inc ORGARAN danaparoid sodium INJECTABLE;INJECTION 020430-001 Dec 24, 1996 5,164,377   Start Trial
Aspen CENESTIN estrogens, conjugated synthetic a TABLET;ORAL 020992-001 Jun 21, 2002 5,908,638   Start Trial
Aspen CENESTIN estrogens, conjugated synthetic a TABLET;ORAL 020992-002 Mar 24, 1999 5,908,638   Start Trial
Aspen CENESTIN estrogens, conjugated synthetic a TABLET;ORAL 020992-004 Mar 13, 2000 5,908,638   Start Trial
Aspen CENESTIN estrogens, conjugated synthetic a TABLET;ORAL 020992-003 Mar 24, 1999 5,908,638   Start Trial
Aspen Global Inc CYCLESSA desogestrel; ethinyl estradiol TABLET;ORAL-28 021090-001 Dec 20, 2000 4,544,554   Start Trial
>Applicant >Tradename >Generic Name >Dosage >NDA >Approval Date >Patent No. >Patent Expiration
Paragraph IV (Patent) Challenges for ASPEN drugs
Drugname Dosage Strength Tradename Submissiondate
➤ Subscribe Tablets 0.625 mg ➤ Subscribe 2009-03-02
➤ Subscribe Tablets 1.25 mg ➤ Subscribe 2008-11-03
➤ Subscribe Tablets 0.3 mg, 0.45 mg and 0.9 mg ➤ Subscribe 2009-03-19
Premature patent expirations for ASPEN

Expiration due to failure to pay maintenance fee

Patent Number Expiration Date
  Start Trial   Start Trial

Supplementary Protection Certificates for Aspen Drugs

Patent Number Supplementary Protection Certificate SPC Country SPC Expiration SPC Description
1429780 13C0012 France   Start Trial PRODUCT NAME: COMBINAISON DE CIPROFLOXACINE ET DE DEXAMETHASONE, EN PARTICULIER DE CHLORHYDRATE DE CIPROFLOXACINE ET DE DEXAMETHASONE; NAT. REGISTRATION NO/DATE: NL 41308 20121214; FIRST REGISTRATION: 48976 20120808
1581193 SPC/GB12/047 United Kingdom   Start Trial PRODUCT NAME: DEXAMETHASONE; REGISTERED: UK EU/1/10/638/001 20100727
1429780 SPC/GB12/058 United Kingdom   Start Trial PRODUCT NAME: A COMBINATION OF CIPROFLOXACIN AND DEXAMETHASONE, PREFERABLY CIPROFLOXACIN HYDROCHLORIDE AND DEXAMETHASONE; REGISTERED: DK DE/11/3337/001/DC 20120808; UK PL000649/0381-0001 20121003
>Patent Number >Supplementary Protection Certificate >SPC Country >SPC Expiration >SPC Description
Similar Applicant Names
Applicants may be listed under multiple names.
Here is a list of applicants with similar names.

Make Better Decisions: Try a trial or see plans & pricing

Serving leading biopharmaceutical companies globally:

AstraZeneca
Colorcon
Express Scripts
Baxter
Dow
Moodys

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.